24-09-2010: Royal DSM N.V announced the acquisition of Microbia, Inc.from Ironwood Pharmaceuticals, Inc. The terms of the acquisition will not be disclosed.
Microbia is a industrial biotechnology research and development specialist. It has developed a highly effective technology platform that enables it to produce high-quality, natural carotenoids (including beta-carotene and canthaxanthin), nutritional products and other specialty materials and chemicals from renewable resources.
Microbia’s sales are still limited. The acquisition will allow DSM to incorporate Microbia’s proprietary platform and world class research and development capabilities and support DSM’s ongoing development of the natural carotenoids market.
Leendert Staal, President and CEO of DSM Nutritional Products commented: “The acquisition of Microbia represents a significant step for DSM in our strategy to accelerate our innovation activities in natural products and fermentation processes. This acquisition allows us to expand our product portfolio as well as our research and development capabilities.”
DSM Pharmaceutical Products announced that it has signed a collaboration agreement with Chemtrix B.V. in the field of Continuous Flow Chemistry to provide sustainable equipment and, development and manufacturing services to the pharmaceutical industry.
The agreement brings together the expe ... more
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, announced that it has signed a biologics contract manufacturing agreement with Paranta Biosciences Ltd of Melbourne , Australia.The contract covers the process development and cGMP manufacture by DSM ... more
In the presence of the governor of Jilin province, Mr. Wang Rulin, the opening ceremony of DSM Sinochem Pharmaceuticals’ newest intermediate plant was celebrated in YuShu, China. The new plant will produce the beta-lactam intermediate 6-APA (6- Aminopenicillanic Acid) for global markets. 6- ... more
Ironwood Pharmaceuticals, Inc. and Bionomics Limited announced that they entered into a collaboration, research, and licensing agreement that will enable Ironwood to develop and commercialize Bionomics’ investigational anti‐anxiety compound BNC210 and other related compounds. The goal of th ... more
Royal DSM N.V announced the acquisition of Microbia, Inc.from Ironwood Pharmaceuticals, Inc. The terms of the acquisition will not be disclosed.
Microbia is a industrial biotechnology research and development specialist. It has developed a highly effective technology platform that enables ... more